The FDA has declined to approve Galderma’s biologics license application for relabotulinumtoxinA, citing manufacturing and testing concerns. According to a company press release, the agency issued a complete response letter (CRL) focusing on site inspection observations and analytical method optimization, though it raised no safety or efficacy issues.
Why did the FDA issue a complete response letter?
The FDA issued the CRL because of observations made during the pre-license inspection of manufacturing sites and issues with analytical method optimization. Galderma stated in its release that it is currently implementing corrective and preventive actions to address these findings. The company is maintaining an open dialogue with the FDA to resolve the observations.
A complete response letter is a communication from the FDA indicating that an application will not be approved in its current form. It outlines the specific deficiencies the company must fix before the agency can grant approval.
Is this the first time the FDA has rejected relabotulinumtoxinA?
No. This is the second CRL Galderma has received for this specific neuromodulator. The first letter arrived in October 2023, citing manufacturing concerns alongside deficiencies in chemistry and control. Galderma resubmitted its biologics license application in February, which the FDA accepted for review before issuing the current rejection.
What is relabotulinumtoxinA and how does it work?
RelabotulinumtoxinA is a ready-to-use liquid neuromodulator designed to treat crow’s feet and glabellar lines. Unlike some traditional neuromodulators that require reconstitution, this product uses “PEARL” technology—precipitation-free extraction and activity-preserving refined liquid technology.
This technology aims to maintain the stability and activity of the toxin in a liquid state, simplifying the preparation process for clinicians.
What does the clinical data show about its effectiveness?
Data from the phase 3 READY trials indicate a rapid onset of action. According to the company, 34% to 39% of participants responded to the treatment by day one. Long-term results varied by the treatment area:
- Glabellar lines: 70% of treated participants maintained a response for six months.
- Crow’s feet: Participants saw a return to baseline after a median of 24.7 weeks.
Where is relabotulinumtoxinA currently available?
While it lacks FDA approval in the United States, the neuromodulator is already approved in 33 markets worldwide. Galderma stated that securing U.S. approval remains a “top priority” and the company plans to respond rapidly to the FDA’s latest requirements.
Frequently Asked Questions
Does the FDA have concerns about the safety of relabotulinumtoxinA?
No. According to Galderma, the FDA did not mention any safety or efficacy concerns in its complete response letter; the issues are strictly related to manufacturing and testing.
What is a biologics license application (BLA)?
A BLA is the request submitted to the FDA for permission to introduce a biological product to the U.S. market. It requires extensive data on the product’s manufacturing process, chemistry, and clinical trial results.
How does this differ from other neuromodulators?
The primary differentiator is the PEARL technology, which allows the product to be “ready-to-use.” This eliminates the need for the manual mixing (reconstitution) required by many other botulinum toxin products currently on the market.